Road to 2025: Recce’s calendar of clinical accomplishment

Sarah Hughan explores Recce Pharmaceuticals and a series of successes advancing a new class of synthetic anti-infectives.

Stockhead's Road to 2025 video series highlights companies' key 2024 achievements and the routes they're plotting towards a successful year ahead.

In this episode, Sarah Hughan explores Recce Pharmaceuticals (ASX:RCE) and a series of successes advancing a new class of synthetic anti-infectives designed to address urgent global health problems.

There are more milestones laid out for the new year, so tune in to find out what to look out for in 2025.

This video was developed in collaboration with Recce Pharmaceuticals, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Originally published as Road to 2025: Recce’s calendar of clinical accomplishment